产品
编 号：F750490
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 2247114-85-6
产品详情
生物活性：
Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal PD-L1 (PD-1/PD-L1) antibody. Adebrelimab has promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC).
体内研究：
Adebrelimab（SHR-1316；200 μg；每周 3 次；持续 21 天）显示出对肿瘤生长的抑制作用。Animal Model:Pathogen free (SPF) BALB/c nude female mice (aged 5-6 weeks) injected with SK-BR-3 cells
Dosage:200 μg
Administration:Three times a week; for 21 days
Result:Significantly inhibited tumor growth.
体外研究：
Adebrelimab (SHR-1316; 0.06- 1mg/mL; 48 hours) 抑制 SK-BR-3 和 AU565 细胞的增殖、迁移、侵袭。Adebrelimab（SHR-1316；0.1-1mg/mL；48 小时）下调 PD-L1、p-PI3K、p-AKT 的表达并上调 FOXO1 的表达。SK-BR-3 and AU565 cells 0.1 mg/mL, 1 mg/mL48 hoursPromoted cell apoptosis.SK-BR-3 and AU565 cells 0.1 mg/mL, 1 mg/mL24 hoursDecreased the migration rate of SK-BR -3 and AU565 cells.SK-BR-3 and AU565 cells 0.1 mg/mL, 1 mg/mL48 hoursDownregulated the expression of PD-L1, p-PI3K, p-AKT and upregulated the expression FOXO1.
Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal PD-L1 (PD-1/PD-L1) antibody. Adebrelimab has promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC).
体内研究：
Adebrelimab（SHR-1316；200 μg；每周 3 次；持续 21 天）显示出对肿瘤生长的抑制作用。Animal Model:Pathogen free (SPF) BALB/c nude female mice (aged 5-6 weeks) injected with SK-BR-3 cells
Dosage:200 μg
Administration:Three times a week; for 21 days
Result:Significantly inhibited tumor growth.
体外研究：
Adebrelimab (SHR-1316; 0.06- 1mg/mL; 48 hours) 抑制 SK-BR-3 和 AU565 细胞的增殖、迁移、侵袭。Adebrelimab（SHR-1316；0.1-1mg/mL；48 小时）下调 PD-L1、p-PI3K、p-AKT 的表达并上调 FOXO1 的表达。SK-BR-3 and AU565 cells 0.1 mg/mL, 1 mg/mL48 hoursPromoted cell apoptosis.SK-BR-3 and AU565 cells 0.1 mg/mL, 1 mg/mL24 hoursDecreased the migration rate of SK-BR -3 and AU565 cells.SK-BR-3 and AU565 cells 0.1 mg/mL, 1 mg/mL48 hoursDownregulated the expression of PD-L1, p-PI3K, p-AKT and upregulated the expression FOXO1.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备